Xilio Therapeutics vs Xencor
XLO and XNCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How XLO and XNCR compare
Xencor is the larger company, worth 59 times as much as Xilio Therapeutics ($2.6B against $44.5M).
Xilio Therapeutics grew revenue faster over the last twelve months (327% versus −28.6% for Xencor).
Xilio Therapeutics keeps more of each dollar of sales as profit, with a net margin of −34.1% compared with −156% at Xencor.
Xilio Therapeutics scores higher on the StockData Score (11 against 5 for Xencor), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | XLO | XNCR |
|---|---|---|
| Size and price | ||
| Market cap | $44.5M | $2.6B |
| Share price | $7.70 | $35.40 |
| Change, 1 year | −21.6% | 153% |
| Change, 5 years | −97.2% | −0.11% |
| Beta (5Y) | −0.00 | −0.09 |
| Employees | 76 | 260 |
| StockData Score | ||
| Total score | 11 (better) | 5 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 2 (better) | 1 |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.7× (better) | 25.1× |
| P/B | 0.6× (better) | 5.2× |
| FCF yield | −138% | −7.9% (better) |
| Fair value | $39.24 | $11.73 |
| Margin of safety | 80.4% (better) | −202% |
| Growth | ||
| Revenue growth (TTM) | 327% (better) | −28.6% |
| Revenue growth, 5Y average | – | 0.47% |
| Profitability | ||
| Operating margin | −48.9% (better) | −206% |
| Net margin | −34.1% (better) | −156% |
| FCF margin | −95.6% (better) | −198% |
| Return on equity | −55.0% | −29.1% (better) |
| Return on invested capital | – | −26.6% |
| Financial health | ||
| Debt / equity | 0.00 | 0.21 (better) |
| Interest coverage | – | −8.0× |
| Current ratio | 4.25 | 6.39 (better) |
| Altman Z-score | −3.01 | 5.19 (better) |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 58.9% | 113% |
| Held by insiders | – | 1.6% |
| Insider net buying, 12 months | $38.3K (better) | −$7.5M |
| Short interest, % of float | – | 17.6% |
Go deeper
- XLO stock overview
- XLO income statement
- XLO valuation and score
- XNCR stock overview
- XNCR income statement
- XNCR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.